At the same time, immunotherapy has also made significant progress, particularly with inhibitors targeting programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) and Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors, which have shown promising results in the treatment of cutaneous melanomas (13). This evidence concerns the gene PDCD1 and cutaneous melanoma.